CHM-2101

N/A

Report date: 2025/04/30 20:00:42

Base Information

Drug NameCHM-2101
Drug Alias NameCadherin 17 chimeric antigen receptor-positive (CAR) T cellsCadherin-17CHM2101CDH17-CAR TCHM-2101 +[6] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived +[4] 
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsCadherin-17 modulators
TargetsCadherin-17
Therapy Area/IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesChimeric Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A